

Procter & Gamble - I.P. Division**IMPORTANT CONFIDENTIALITY NOTICE**

The documents accompanying this telecopy transmission contain confidential information belonging to the sender which is legally protected. The information is intended only for the use of the individual or entity named below. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopied information is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone (collect) to arrange for return of the telecopied document to us.

**FACSIMILE TRANSMITTAL SHEET AND
CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8****RECEIVED
CENTRAL FAX CENTER****APR 07 2004****OFFICIAL****TO United States Patent and Trademark Office**

Fax No. 703-872-9306

Phone No.

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on April 7, 2004 to the above-identified facsimile number.

Linda S. Jernigan (Signature)

FROM: Linda S. Jernigan Typed or printed name of person signing Certificate)

Fax No. 513-622-3300

Phone No. 513-622-2811

Listed below are the item(s) being submitted with
this Certificate of Transmission:**

- 1) Correction to Serial No. for Information
Disclosure Statement - orig. w/copy
- 2) Information Disclosure Statement - 4
pages
- 3) Information Disclosure Statement &
PTOSB08 for Serial No. 09/756/452 - 3
pages

Number of Pages including this Page 10
Inventor(s):

Davenport et al.

S.N.: 10/624017

Filed: July 21, 2003

Case: P124C2

COMMENTS:

P&G Case P124C2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of :
Davenport et al. : Confirmation No. 5722
Serial No. 10/624017 : Group Art Unit 1614
Filed July 21, 2003 : Examiner

For Process And Composition For Controlling Fecal Hair Excretion & Trichobezoar Formation

CORRECTION TO SERIAL NO. FOR INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Please note this is to correct the serial number (and Confirmation No. and Art Unit No.) that was inadvertently communicated on the Information Disclosure Statement submitted on April 5, 2004 (please find a copy attached that was originally submitted showing the correct serial number). Please delete serial no "10/138790" and insert "—10/624017—".

Therefore, no fee is believed to be due. However, I have included a duplicate copy of this letter to facilitate charging of the fee if necessary to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company.

Respectfully submitted,



By Linda S. Jernigan

IP Administrator

(513) 622-2811

Date: April 7, 2004
Customer No. 27752

P&G Case P124C2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of :
Davenport et al. : Confirmation No. 5722
Serial No. 10/624017 : Group Art Unit 1614
Filed July 21, 2003 : Examiner

For Process And Composition For Controlling Fecal Hair Excretion & Trichobezoar Formation

CORRECTION TO SERIAL NO. FOR INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Please note this is to correct the serial number (and Confirmation No. and Art Unit No.) that was inadvertently communicated on the Information Disclosure Statement submitted on April 5, 2004 (please find a copy attached that was originally submitted showing the correct serial number). Please delete serial no "10/138790" and insert "-10/624017-".

Therefore, no fee is believed to be due. However, I have included a duplicate copy of this letter to facilitate charging of the fee if necessary to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company.

Respectfully submitted,

Linda S. Jernigan
By Linda S. Jernigan
IP Administrator
(513) 622-2811

Date: April 7, 2004
Customer No. 27752



P&G Case P124C2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of :
 Davenport et al. : Confirmation No. 7751 5722
 Serial No. ~~40438799~~ 10/624017 : Group Art Unit ~~1651~~ 1614
 Filed July 21, 2003 : Examiner

For Process And Composition For Controlling Fecal Hair Excretion & Trichobezoar Formation

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
 P. O. Box 1450
 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made below in a Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. ☐ 37 C.F.R. §1.97 (b)(1) - U.S. Direct (within 3-months of filing a regular application or converted provisional)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(1), is being filed within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. ☐ 37 C.F.R. §1.97 (b)(2) - Via PCT (within 3 mo. of Nat'l Stage Entry)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(2), is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application. Therefore, no fee is believed to be due.

3. ☒ 37 C.F.R. §1.97 (b)(3) - (>3 mo. after filing direct or nat'l stage entry, but before 1st O.A.)

This information disclosure statement is being submitted under 37 C.F.R. §1.97 (b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter is enclosed to facilitate charging of the fee, if necessary.

THE FOLLOWING IS ADDITIONAL INFORMATION PERTAINING TO (2) OR (3) MARKED WITH AN (X) ABOVE.

(a) ☐ The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that both a copy of the International Search Report and copies of the references cited therein are present in the national stage file. In accordance with MPEP §1893.03(g), it is respectfully requested that the Examiner note the consideration of these references in the first Office Action via the PTO-892 form.

(b) ☐ The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that a copy of the International Search Report is present in the national stage file. Copies of the references cited in that report are enclosed.

(c) ☐ The Notification of Acceptance of this Application Under 35 U.S.C. §371 does not indicate that a copy of the International Search Report and copies of the references cited are present in the national stage file. Copies of the International Search Report and references are attached.

4. ☐ 37 C.F.R. §1.97 (b)(4) - (before the mailing of a first Office Action after the filing of a request for continued examination under §1.114)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(4), is being filed with the Request for Continued Examination (RCE) under 37 C.F.R. §1.114.

5. ☐ Information to be Considered with CPA Filing. This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 CFR 1.53(d).

6. ☐ 37 C.F.R. §1.97(c) with fee payment - (use after 1st Office Action & before Final Office Action or Notice of Allowance)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

☒ (1) Copies of the cited references were previously cited by or submitted to the USPTO in prior application Case No. P124, U.S. Patent Application Serial No. 09/756,452, filed January 8, 2001. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of those documents are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). However, copies of the IDS statement and Supplemental IDS are attached for reference.

OR

☐ (2) Copies of the cited documents are enclosed.

OR

☐ (3) Copies of all said documents, except document No.'s _____, were submitted and considered in parent application U.S. Patent Application Serial No. _____, filed _____. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of document No.'s _____ are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of document No.'s _____ are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.


☐ (4) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.

☐ (5) Applicants also respectfully request the Examiner to consider and make of record the copending applications listed on the attached page.



Additional information is attached.

Respectfully submitted,

By 
Kelly L. McDow-Dunham
Attorney or Agent for Applicant(s)
Registration No. 43,787
(513) 622-0159

Date: April 5, 2004

Customer No. 27752

(P124C IDS.doc)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of

Applicants : Gary M. Davenport, Gregory D. Sunvold,
Gregory A. Reinhart and Michael G. Hayek
Serial No. : 09/756,452
Filed : 01/08/2001
Title : PROCESS AND COMPOSITION FOR CONTROLLING FECAL
HAIR EXCRETION AND TRICHOBEZOAR FORMATION
Docket : IAM 0574 PA
Art Unit : 1642

Assistant Commissioner for Patents
Washington, DC 20231

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Assistant Commissioner for Patents, Washington, D.C. 20231 on
April 6, 2001.

Susan M. Juma

Patent Agent

Reg. No. 38,769

Sir:

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56, 1.97, AND 1.98

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 CFR §1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 CFR §1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 CFR §1.97(h), constitute an admission that any patent, publication, or other information referred to is, or is considered to be, material to the patentability of this invention. Further, pursuant to 37 CFR §1.97(g), the filing of this Statement should not be construed as a statement that a search has been made or that no other material information exists.

A listing of all items of information cited is attached on PTO/SB/08A, a substitute for form 1449A/PTO. Copies of the items are enclosed for the convenience of the Examiner.

Serial No. 09/756,452
Docket No. IAM 0574 PA

This Information Disclosure Statement is being filed within the period set forth in 37 CFR §1.97(b) because it is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in 37 CFR §1.491 in an international application.

Respectfully submitted,

KILLWORTH, GOTTMAN, HAGAN
& SCHAEFF, L.L.P.

By Susan M. Luma
Susan M. Luma
Patent Agent
Registration No. 38,769

One Dayton Centre
One South Main Street, Suite 500
Dayton, Ohio 45402-2023
Telephone: (937) 223-2050
Facsimile: (937) 223-0724

SML/vlc
Encls.

